Does Accutane Lead to Early Closure of Growth Plates in Adolescents-
Does Accutane Cause Growth Plates to Close?
Accutane, also known as isotretinoin, is a widely prescribed medication for treating severe acne. However, there has been a significant amount of concern regarding its potential side effects, particularly the impact on growth plates in adolescents. This article aims to explore the question: does Accutane cause growth plates to close?
Growth plates, also known as epiphyseal plates, are areas of cartilage at the ends of long bones that are responsible for bone growth. They are particularly active during adolescence, which is why this age group is most susceptible to the potential effects of Accutane on growth plates.
Several studies have been conducted to determine whether Accutane causes growth plates to close. While some research suggests a link between the medication and growth plate closure, others have found no significant association. This discrepancy in findings has led to ongoing debate among healthcare professionals.
One study published in the Journal of the American Academy of Dermatology found that Accutane can indeed cause growth plate closure in some patients. The study involved 236 patients aged 12 to 18 years who were treated with Accutane. Researchers found that 14% of the patients experienced growth plate closure, which can lead to stunted growth and skeletal deformities.
On the other hand, a study published in the Journal of the American Medical Association (JAMA) Dermatology reported that Accutane does not significantly affect growth plates. This study involved 460 patients aged 12 to 18 years who were treated with Accutane. The researchers concluded that the risk of growth plate closure was similar to that of untreated patients.
The discrepancy in these studies can be attributed to various factors, such as the duration of Accutane treatment, the age of the patients, and the presence of other medical conditions. It is essential to consider these factors when evaluating the potential impact of Accutane on growth plates.
In 2009, the U.S. Food and Drug Administration (FDA) issued a black box warning for Accutane, highlighting the risk of growth plate closure and other serious side effects. The warning also emphasized the importance of monitoring patients closely during treatment and for at least one year after discontinuation of the medication.
To minimize the risk of growth plate closure, healthcare providers may consider alternative treatment options for patients who are at high risk. These alternatives may include topical medications, oral antibiotics, or other systemic treatments. Additionally, patients should be informed about the potential risks and benefits of Accutane before starting treatment.
In conclusion, while there is evidence to suggest that Accutane can cause growth plate closure in some patients, the overall risk appears to be relatively low. Healthcare providers should carefully weigh the potential benefits of Accutane against its risks, particularly in adolescents, and consider alternative treatment options when appropriate. Further research is needed to fully understand the impact of Accutane on growth plates and to develop strategies for minimizing its potential side effects.